Allogene Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 5 | -$0.51 | -$0.36 | -$0.41 |
| Q2 2024 | 5 | -$0.43 | -$0.31 | -$0.35 |
| Q3 2024 | 4 | -$0.41 | -$0.29 | -$0.33 |
| Q4 2024 | 11 | -$0.49 | -$0.24 | -$0.32 |
| Q1 2025 | 8 | -$0.39 | -$0.25 | -$0.33 |
| Q2 2025 | 5 | -$0.41 | -$0.29 | -$0.33 |
| Q3 2025 | 4 | -$0.41 | -$0.29 | -$0.33 |
| Q4 2025 | 5 | -$0.41 | -$0.29 | -$0.33 |
| Q1 2026 | 3 | -$0.29 | -$0.21 | -$0.24 |
| Q2 2026 | 4 | -$0.30 | -$0.21 | -$0.24 |
| Q3 2026 | 3 | -$0.30 | -$0.22 | -$0.25 |
| Q4 2026 | 4 | -$0.29 | -$0.21 | -$0.24 |
Allogene Therapeutics, Inc. Earnings Date And Information
Allogene Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.27 earnings per share for the quarter, topping analysts' consensus estimates of $-0.34 by $0.07. The company had revenue of 0 for the quarter and had revenue of 95,000 for the year. Allogene Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-2.09 diluted earnings per share) and currently has a price-to-earnings ratio of -1.63. Allogene Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Allogene Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.34 | -$0.32 | 0.02 | $10,769 | $0 |
| 08/07/2024 | Q2 2024 | -$0.35 | -$0.35 | 0 | $2.01 M | $0 |
| 05/13/2024 | Q1 2024 | -$0.38 | -$0.38 | 0 | $22,000 | |
| 03/14/2024 | Q4 2023 | -$0.47 | -$0.51 | -0.04 | $21,000 | |
| 11/02/2023 | Q3 2023 | -$0.53 | -$0.37 | 0.16 | $14,462 | $43,000 |
| 08/02/2023 | Q2 2023 | -$0.59 | -$0.53 | 0.06 | $13,467 | $44,000 |
| 05/03/2023 | Q1 2023 | -$0.63 | -$0.68 | -0.05 | $52,000 | |
| 03/14/2024 | Q4 2022 | -$0.47 | -$0.65 | -0.18 | $47,000 | |
| 11/02/2022 | Q3 2022 | -$0.62 | -$0.58 | 0.04 | $12,385 | $49,000 |
| 08/09/2022 | Q2 2022 | -$0.61 | -$0.52 | 0.09 | $8,333 | $86,000 |
| 05/04/2022 | Q1 2022 | -$0.59 | -$0.56 | 0.03 | $61,000 | |
| 02/23/2022 | Q4 2021 | -$0.61 | -$0.54 | 0.07 | $51,000 | |
| 11/04/2021 | Q3 2021 | -$0.56 | -$0.57 | -0.01 | $263,857 | $49,000 |
| 08/04/2021 | Q2 2021 | -$0.55 | -$0.53 | 0.02 | $13.92 M | $44,000 |
| 05/05/2021 | Q1 2021 | -$0.48 | -$0.25 | 0.23 | $38.35 M | |
| 02/25/2021 | Q4 2020 | -$0.56 | -$0.53 | 0.03 | $0 | |
| 11/04/2020 | Q3 2020 | -$0.55 | -$0.52 | 0.03 | $0 | |
| 08/05/2020 | Q2 2020 | -$0.55 | -$0.53 | 0.02 | $0 | |
| 05/06/2020 | Q1 2020 | -$0.57 | -$0.50 | 0.07 | $0 | |
| 02/27/2020 | Q4 2019 | -$0.69 | -$0.58 | 0.11 | $0 |
Allogene Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Allogene Therapeutics, Inc.'s earnings date?
Allogene Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
-
Did Allogene Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Allogene Therapeutics, Inc. (:ALLO) reported $-0.27 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.34 by $0.07.
-
How can I listen to Allogene Therapeutics, Inc.'s earnings conference call?
The conference call for Allogene Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Allogene Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Allogene Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Allogene Therapeutics, Inc. generate each year?
Allogene Therapeutics, Inc. (:ALLO) has a recorded annual revenue of $95,000.
-
How much profit does Allogene Therapeutics, Inc. generate each year?
Allogene Therapeutics, Inc. (:ALLO) has a recorded net income of $95,000. Allogene Therapeutics, Inc. has generated $-2.09 earnings per share over the last four quarters.
-
What is Allogene Therapeutics, Inc.'s price-to-earnings ratio?
Allogene Therapeutics, Inc. (:ALLO) has a price-to-earnings ratio of -1.63 and price/earnings-to-growth ratio is -0.53.
